Keytruda 100 mg Injection 4 ml

Keytruda 100 mg Injection 4 ml is an anti-cancer medicine used in the treatment of various types of cancers in both adult and paediatric populations. Cancer is a disease caused due to the abnormal growth of cells that divide uncontrollably. This medicine is used in treating advanced renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, non-small cell lung cancer, metastatic melanoma, small cell lung cancer, gastric cancer, classical Hodgkin’s disease, urothelial carcinoma, cervical cancer, primary mediastinal large B-cell lymphoma, endometrial cancer, microsatellite instability-high cancer, and head and neck cancer.

Keytruda 100 mg Injection 4 ml contains Pembrolizumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the action of a programmed death receptor-1 (PD-1) and thereby stops the abnormal growth of cancer cells.

Keytruda 100 mg Injection 4 ml may cause certain side effects such as diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, cough, shortness of breath, muscle/joint pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for a longer duration. Keytruda 100 mg Injection 4 ml will be administered by an oncologist. Avoid self-administration.

Avoid taking Keytruda 100 mg Injection 4 ml if you are allergic to it or any other components of it. Before taking Keytruda 100 mg Injection 4 ml, inform your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis, Crohn’s disease, any history of organ transplants, received a stem cell transplant that uses donor stem cells (allogeneic), undergone radiation treatment to the chest or any other medical conditions. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy and breastfeeding.

Keytruda 100 mg Injection 4 ml is used in the treatment of various cancers. The detailed uses of Keytruda 100 mg Injection 4 ml are as follows:

• Treatment of cancers: Keytruda 100 mg Injection 4 ml is used in the treatment of various cancer conditions such as Renal Cell Carcinoma, Hepatocellular carcinoma, Metastatic Melanoma, non-small cell lung cancer, Malignant pleural mesothelioma, Stomach Cancer, Squamous cell carcinoma of the head and neck, Cervical cancer, and Urothelial carcinoma.

• It is advised to follow your doctor's instructions on the dosage and timing of Keytruda 100 mg Injection 4 ml for effective use.
• Keytruda 100 mg Injection 4 ml will be administered by the doctor or nurse.
• Do not self-administer.

Keytruda 100 mg Injection 4 ml contains Pembrolizumab, which is used in the treatment different types of cancers. It works by inhibiting the action of a programmed death receptor-1 (PD-1) that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body.

To treat your condition effectually, continue taking Keytruda 100 mg Injection 4 ml for the period that your doctor has prescribed. Keytruda 100 mg Injection 4 ml may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis (hepatotoxicity), nephritis, endocrinopathies (such as adrenal insufficiency, diabetes, thyroid disorders), pneumonitis, and dermatologic reactions (such as Stevens-Johnson syndrome, epidermal necrolysis). It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, received a stem cell transplant that uses donor stem cells (allogeneic), undergone radiation treatment to the chest and autoimmune disorders such as ulcerative colitis, or Crohn’s disease while receiving Keytruda 100 mg Injection 4 ml. Discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 2 years of age as the safety and efficacy are not established.